OncoMatch/Clinical Trials/NCT06305754

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Is NCT06305754 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for non-small cell lung cancer (nsclc).

Treatment: Sacituzumab tirumotecan · Pemetrexed · Carboplatin · H1 Receptor Antagonist · H2 Receptor Antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid Mouthwash (dexamethasone or equivalent) — The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).